CA2924460A1 - Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring - Google Patents

Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring Download PDF

Info

Publication number
CA2924460A1
CA2924460A1 CA2924460A CA2924460A CA2924460A1 CA 2924460 A1 CA2924460 A1 CA 2924460A1 CA 2924460 A CA2924460 A CA 2924460A CA 2924460 A CA2924460 A CA 2924460A CA 2924460 A1 CA2924460 A1 CA 2924460A1
Authority
CA
Canada
Prior art keywords
alpha
pgf
atrophic
pharmaceutical composition
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2924460A
Other languages
English (en)
French (fr)
Inventor
Warren J. Scherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of CA2924460A1 publication Critical patent/CA2924460A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
CA2924460A 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring Abandoned CA2924460A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361960740P 2013-09-26 2013-09-26
US61/960,740 2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (1)

Publication Number Publication Date
CA2924460A1 true CA2924460A1 (en) 2015-04-02

Family

ID=52282772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2924460A Abandoned CA2924460A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Country Status (11)

Country Link
US (1) US10039770B2 (https=)
EP (1) EP3049088B1 (https=)
JP (1) JP6453318B2 (https=)
KR (1) KR102221499B1 (https=)
CN (1) CN105658221B (https=)
AU (1) AU2014326298B2 (https=)
BR (1) BR112016006426A2 (https=)
CA (1) CA2924460A1 (https=)
MX (1) MX374476B (https=)
RU (1) RU2690183C2 (https=)
WO (1) WO2015044788A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319607A4 (en) * 2015-07-09 2019-04-03 Galderma S.A. METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) * 1999-05-24 2003-01-10 Парамонов Борис Алексеевич Способ дермабразии
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
JP2011520902A (ja) * 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 創傷の治癒を促進する方法
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) * 2010-08-24 2011-04-27 苏州圣诺生物医药技术有限公司 促进皮肤伤口无疤痕愈合的siRNA及应用
EP2648676A4 (en) * 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
CA2826232C (en) * 2011-01-31 2019-09-17 Allergan, Inc. Compositions and uses of synergistic effective amounts of bimatoprost and minoxidil for enhancing hair growth
US20120251613A1 (en) 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
US9051294B2 (en) * 2013-04-30 2015-06-09 Allergan, Inc. Therapeutic agents

Also Published As

Publication number Publication date
KR102221499B1 (ko) 2021-03-02
US10039770B2 (en) 2018-08-07
CN105658221B (zh) 2022-05-10
MX374476B (es) 2025-03-06
BR112016006426A2 (pt) 2017-08-01
JP2016531872A (ja) 2016-10-13
MX2016003650A (es) 2016-06-24
RU2690183C2 (ru) 2019-05-31
AU2014326298B2 (en) 2019-07-04
US20160228453A1 (en) 2016-08-11
RU2016110925A3 (https=) 2018-07-13
JP6453318B2 (ja) 2019-01-16
RU2016110925A (ru) 2017-11-01
EP3049088A1 (en) 2016-08-03
WO2015044788A1 (en) 2015-04-02
KR20160055941A (ko) 2016-05-18
AU2014326298A1 (en) 2016-04-07
EP3049088B1 (en) 2021-02-17
CN105658221A (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
JP6966455B2 (ja) 侵襲的且つ非侵襲的な処置上のスキンケアのための組成物及び方法
AU2008341112B2 (en) Pre-surgical treatment
US7833542B2 (en) Method and composition for the treatment of scars
US20120295914A1 (en) Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid
CN105848640A (zh) 包含聚己内酯聚合物的局部用凝胶组合物以及用于增强有益剂的局部施用的方法
JP7421558B2 (ja) 組織修復に適用されるピルフェニドンを含有する半固体油性医薬組成物
US5520919A (en) Vitamin A palmitate composition and methodology for repairing and rejuvenating human skin
JP2014518239A (ja) 皮膚反応を低減するための新規な安定麻酔組成物
AU2014326298B2 (en) Prostaglandin F2alpha and analogues thereof for treating atrophic cutaneous scarring
AU2012324544B2 (en) Method for treating capillary hemangiomas
US20190000936A1 (en) Prophylactic normalization of cutaneous wound repair
Colom Scar Care after Surgical Treatment in Oncology Patients
WO2025208042A1 (en) Silk peptides topical formulations and methods of their use
KR20150115303A (ko) 폴리감마글루탐산을 함유하는 창상치료용 조성물

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220830